Description: Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company's lead pharmaceutical drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. Its products also include BXT-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. The company was founded in 2017 and is headquartered in Newton, Massachusetts.
Home Page: www.bioxytraninc.com
233 Needham Street
Newton,
MA
02464
United States
Phone:
617-454-1199
Officers
| Name | Title |
|---|---|
| Dr. David Platt Ph.D. | Chairman, CEO & Pres |
| Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A. | CFO, Treasurer & Sec. |
| Mr. Michael Sheikh B.S. | Exec. VP of Bus. Devel. |
Exchange: OTCCE
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 532.5585 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |